Objective To analyze the relationship between serum long-chain non-coding ribonucleic acid taurine up-regulation gene 1(lncRNA TUG1) and microribonucleic acid-144(miR-144) expression and the prognosis of LN patients with lupus nephritis(LN). Methods A total of 104 LN patients admitted to the Department of Rheumatology and Immunology of Suining Central Hospital from January 2020 to June 2021 were selected as the LN group, and they were divided into 36 subgroups with poor prognosis and 68 cases with good prognosis according to whether end-stage renal disease(ESRD) occurred during the follow-up period, and 40 healthy patients with physical examination during the same period were selected as the healthy control group. The expression of serum lncRNA TUG1 and miR-144 was detected by real-time quantitative polymerase chain reaction kit. The binding sites of lncRNA TUG1 and miR-144 were predicted by TargetScan, and the correlation between serum lncRNA TUG1 and miR-144 expression in LN patients was analyzed by Pearson correlation. Multivariate logistic regression analysis was used to analyze the risk factors of poor prognosis in LN patients, and receiver operating characteristics(ROC) curves were used to analyze the predictive value of serum lncRNA TUG1 and miR-144 expression in poor prognosis of LN patients. Results Compared with the healthy control group, the expression of serum lncRNA TUG1 in the LN group decreased and the expression of miR-144 increased(t/P=15.885/<0.001 and 15.808/<0.001). The TargetScan website predicted that there was a binding site between lncRNA TUG1 and miR-144. Pearson correlation analysis showed that serum lncRNA TUG1 was negatively correlated with miR-144 expression in LN patients(r=-0.797, P<0.001). After 2 years of follow-up, the incidence of ESRD in 104 patients with LN was 34.62%(36/104). Multivariate Logistic regression analysis showed that stage 4 of chronic kidney disease and elevated miR-144 were independent risk factors for poor renal prognosis in patients with LN [OR(95%CI)=1.197(1.062～1.349), 1.108(1.047～1.172)], complete remission after induction therapy and estimated glomerular filtration rate and elevated lncRNA TUG1 were independent protective factors [OR(95%CI)=0.305(0.101-0.923), 0.979(0.960-0.998), 0.841(0.750-0.943)], ROC curve analysis showed that the expression of serum lncRNA TUG1 and miR-144 and the area under the curve(AUC) of the two combined predictions of poor renal prognosis in LN patients were 0.772, 0.773 and 0.911, respectively, and the AUC predicted by the two was the largest(Z/P=3.239/0.001、3.247/0.001).Conclusion The low expression of serum lncRNA TUG1 and the high expression of miR-144 in LN patients were associated with poor renal prognosis, and the combined value of the two in predicting the poor renal prognosis of LN was higher.

Objective To investigate the expression and significance of microRNAs miR-155 and miR-182 in serum of hemodialysis patients with end-stage renal disease. Methods A total of 112 patients with end-stage renal disease who received diagnosis and treatment and underwent hemodialysis in the 971st Navy Hospital, Qingdao Municipal Hospital, and Qingdao Haici Hospital from May 2019 to May 2022 were collected as the end-stage renal disease group, and 112 healthy patients who underwent physical examination during the same period were selected as the healthy control group. Real-time quantitative PCR(qRT-PCR) was used to detect the expression of serum miR-155 and miR-182. Pearson method was used to analyze the correlation between serum miR-155 and miR-182 levels in patients with end-end renal disease. Logistic regression analysis was performed to analyze the influencing factors of the prognosis of dialysis patients with end-end renal disease. The receiver operating characteristic(ROC) curve was used to analyze the predictive value of serum miR-155 and miR-182 expression levels in the prognosis of hemodialysis patients with end-stage renal disease. Results The serum expression levels of miR-155 and miR-182 in the end-renal disease group were significantly higher than those in the healthy control group(t/P=12.719/<0.001, 27.901/<0.001). There were no significant differences in the ratio of males and females, age, BMI, proportion of primary disease, dialysis time, serum phosphorus(P), total cholesterol(TC), triacylglycerol(TG), high-density lipoprotein cholesterol(HDL-C) and low-density lipoprotein cholesterol(LDL-C) between the two subgroups(P>0.05), and compared with the survival subgroup, the hemoglobin(Hb) and albumin(Alb) of the death subgroup were significantly reduced(t/P=15.069/<0.001, 9.629/<0.001), serum calcium(Ca) and high-sensitivity C-reactive protein(hs-CRP) and serum miR-155 and miR-182 were increased(t/P=21.174/<0.001, 40.68/<0.001, 6.629/<0.001, 8.497/<0.001). The serum expressions of miR-155 and miR-182 in hemodialysis patients with end-end renal disease were positively correlated(r=0.516, P<0.001). Low Hb, high serum Ca, high hs-CRP, high Alb, high miR-155, and high miR-182 were independent risk factors for the prognosis of dialysis patients with end-renal disease [OR(95%CI)=3.189(1.052-9.670), 4.387(1.175-16.375), 5.527(1.220-25.048), 2.058(1.251-3.386), 5.561(2.413-12.817), 3.189(1.052-9.670)]; The area under the curve(AUC) of serum miR-155 and miR-182 and their combination were 0.827, 0.793 and 0.956, respectively, which were better than those predicted by serum miR-155 and miR-182 separately(Z/P=2.251/0.024, 2.797/0.005). Conclusion The serum expression levels of miR-155 and miR-182 in hemodialysis patients with end-stage renal disease are elevated, and the combination of miR-155 and miR-182 may better predict the prognosis of hemodialysis patients with end-stage renal disease.

Objective To investigate the effect of tenofovir dipivoxil fumarate on immune and inflammatory response levels in patients with chronic severe hepatitis B. Methods One hundred and fourty patients with chronic severe hepatitis B were selected from the Infectious Diseases Department of Haikou People's Hospital from March 2021 to March 2022. They were randomly divided into an observation group of 57 patients and a control group of 57 patients. The control group received routine support therapy and entecavir oral treatment, while the observation group received routine support therapy and tenofovir dipivoxil fumarate oral treatment. Compare the liver function indicators(ALT, AST, TBil, Alb), cellular immune related indicators(CD4+T lymphocyte ratio, CD8+T lymphocyte ratio, CD4+/CD8+ratio), and serum inflammatory related indicators(TGF) between two groups of patients within 6 months of treatment-β 1. IL-6, TRIM5 α、 The levels of SOCS-1 and PD-1, as well as the incidence of adverse drug reactions. Results After 6 months of treatment, the serum ALT, AST, and TBil levels in the observation group were lower than those in the control group, while Alb levels were higher than those in the control group(t/P=10.632/<0.001, 6.216/<0.001, 6.090/<0.001, 3.943/<0.001). The proportion of CD4+T lymphocytes and CD4+/CD8+ratio were higher than those in the control group, while the proportion of CD8+T lymphocytes was lower than that in the control group(t/P=6.229/<0.001, 5.567/<0.001, 3.737/<0.001). The levels of serum TGF-β, IL-6 and PD-1 in the control group were lower than those in the control group; TRIM5 α The levels of SOCS-1 were higher than those of the control group(t/P=7.249/<0.001, 5.395/<0.001, 8.658/<0.001, 13.451/<0.001, 7.195/<0.001). During the treatment process, the total incidence of adverse drug reactions in the observation group was lower than that in the control group(χ2/P=4.222/0.040). Conclusion Tenofovir dipivoxil fumarate can significantly improve liver function and cellular immune function in patients with chronic severe hepatitis B, while significantly inhibiting inflammatory reactions in the patient's body and reducing the incidence of adverse reactions caused by antiviral drugs.

Objective To analyze the correlation between keratin 7(KRT7), p53 protein and clinical pathology and prognosis of bladder cancer.Methods Retrospective analysis was made on the clinical data of 105 patients with bladder cancer admitted to the Pathology Department of the Second People's Hospital of Lianyungang City, Jiangsu Province from February 2016 to March 2019. All patients received radical surgery for bladder cancer. During the surgery, the cancerous tissues and adjacent tissues were taken, and the expression levels of KRT7 and p53 proteins in cancerous tissues and adjacent tissues were detected by immunohistochemical method, Cox was used to analyze the prognostic factors of bladder cancer patients, and Kaplan Meier method was used to analyze the relationship between KRT7 protein, p53 protein expression and the prognosis of bladder cancer patients.Results The positive rate of KRT7 protein in cancer tissue is lower than that in adjacent tissues(χ2/P=23.786/<0.001), the positive rate of p53 protein is higher than that of adjacent tissues(χ2/P=28.651/<0.001); Patients with poorly differentiated T2 to T4 stages, tumor diameter ≥ 3 cm, and KRT7 protein positivity in cancer tissue are lower than those with moderately well differentiated Ta to T1 stages, and tumor diameter<3 cm(χ2/P=4.940/0.026, 11.299/<0.001, 5.379/0.020), the positive rate of p53 protein is higher than that of patients with Ta-T1 stage, medium to high differentiation, and tumor diameter<3 cm(χ2/P=22.459/<0.001, 12.093/<0.001, 25.527/<0.001); After 3 years of follow-up, 4 of 105 bladder cancer patients lost the follow-up, and 34 of the remaining 101 patients died, with a case fatality rate of 33.66%. Cox analysis showed that T2～T4 stage, poor differentiation, tumor diameter ≥ 3 cm, KRT7 protein negative and p53 protein positive were the risk factors for the prognosis of bladder cancer patients [HR(95%CI)=3.935(1.730-8.952), 3.575(1.572-8.133), 3.515(1.545-7.996), 4.933(2.169-11.222), 3.762(1.654-8.558)]. The survival rate of KRT7 protein positive patients is higher than that of KRT7 protein negative patients(χ2=5.238, P=0.022); The survival rate of p53 protein negative patients is higher than that of p53 protein positive patients(χ2=5.115, P=0.024). Conclusion The expression of KRT7 and p53 protein in bladder cancer tissue is closely related to the degree of differentiation, tumor diameter, clinical stage and prognosis.

Objective To study the serum levels of cysteine protease inhibitor 6(CST6) and interleukin-17A(IL-17A) in patients with multiple myeloma bone disease(MMBD) and their relationship with the severity and prognosis of MMBD. Methods Eighty patients with MMBD diagnosed and treated in the Hematology Department of the First Affiliated Hospital of Xi'an Jiaotong University from February 2019 to January 2020 were selected as the MMBD group, and 50 patients with multiple myeloma without bone disease diagnosed and treated during the same period were selected as the control group. Enzyme linked immunosorbent assay was used to detect serum levels of CST6 and IL-17A; The correlation was analyzed using Spearman rank correlation analysis; The evaluation value of serum CST6 and IL-17A on the prognosis of MMBD by analyzing the working characteristic curve of subjects; Multivariate Cox regression analysis of factors affecting the prognosis of MMBD patients; Kaplan Meier survival analysis of the impact of serum CST6 and IL-17A levels on the prognosis of MMBD patients. Results Compared with the control group, the serum CST6 level in the MMBD group decreased and the serum IL-17A level increased significantly(t/P=39.798/<0.001, 18.241/<0.001). Serum CST6 was significantly negatively correlated with MMBD bone disease grading, while serum IL-17A was significantly positively correlated with MMBD bone disease grading(r/P=-0.721/<0.001, 0.664/<0.001); The area under the curve(AUC) of serum CST6, IL-17A, and their combination for evaluating the prognosis of MMBP patients were 0.812, 0.888, and 0.931, respectively. The combination of the two had the highest AUC for evaluating the prognosis of MMBP patients(Z/P=5.147/<0.001, 4.784/<0.001); The 3-year cumulative survival rate of the CST6 low expression subgroup is lower than that of the CST6 high expression subgroup(χ2=7.933, P=0.005), the 3-year cumulative survival rate of the IL-17A high expression subgroup was lower than that of the IL-17A low expression subgroup(χ2=22.802, P<0.001); ISS stage Ⅲ, bone disease grade 4, and high serum IL-17A are independent risk factors affecting the prognosis of MMBD patients. High serum CST6 is an independent protective factor affecting the prognosis of MMBD patients [OR(95%CI)=1.594(1.252-2.028), 1.589(1.258-2.006), 1.451(1.120-1.879), 0.703(0.537-0.919)].Conclusion The decrease of serum CST6 and the increase of IL-17A levels in MMBD patients are independent factors affecting the prognosis of MMBD patients, which are related to the severity of their condition.